Abstract-Hypertension is associated with microvascular and macrovascular brain injury but its direct influence on the cerebral circulation is not fully clear. Our objective was to investigate the association of hypertension with global and regional cerebral vasoreactivity to CO 2 using continuous arterial spin labeling MRI, independent of stroke and white matter hyperintensities. Participants (nϭ62; mean age: 66.7Ϯ1.0 years, 55% women, 84% white, 65% hypertension, 47% stroke) underwent arterial spin labeling perfusion MRI during normal breathing, 5% CO 2 rebreathing, and hyperventilation, as well as 24-hour ambulatory blood pressure monitoring. Vasoreactivity was the slope of the regression between cerebral perfusion and end-tidal CO 2 . White matter hyperintensity volumes were quantified. Nighttime dipping was calculated as the percentage decline in nighttime/daytime blood pressure. After accounting for stroke and white matter hyperintensity volume, hypertensive participants had lower global vasoreactivity (1.11Ϯ0.13 versus 0.43Ϯ0.1 mL/100 g per minute per millimeter of mercury; Pϭ0.0012). Regionally, this was significant in the frontal, temporal, and parietal lobes. Higher mean systolic blood pressure was associated with lower vasoreactivity (decreased by 0.11 U/10-mm Hg increase in systolic blood pressure; Pϭ0.04), but nighttime dipping was not (Pϭ0.2). The magnitude of decrease in vasoreactivity in hypertension without stroke was comparable to the magnitude of decrease in vasoreactivity in stroke without hypertension. Hypertension has a direct negative effect on the cerebrovascular circulation independent of white matter hyperintensities and stroke that is comparable to that seen with stroke. Because lower vasoreactivity is associated with poor outcomes, studies of the impact of antihypertensive on vasoreactivity are important. (Hypertension. 2010;56:859-864.)
D
ecline in cerebrovascular reactivity is associated with cognitive decline, [1] [2] [3] [4] slower gait speed, and possibly falls. 5 Previous studies suggest that hypertension may have an influence on cerebrovascular reactivity. 6 Most of these studies have assessed cerebrovascular reactivity in hypertension by measuring changes in cerebral blood flow at the middle cerebral artery in response to changes to end-tidal carbon dioxide (CO 2 ) using transcranial Doppler (TCD). 7 Although these studies have shown that hypertensives may have lower cerebral vasoreactivity to CO 2 , gaps in our knowledge remain unanswered. Hypertension is a major risk factor for stroke and white matter hyperintensities (WMHs), both associated with impaired cerebral vasoreactivity. 8, 9 TCD cannot assess whether the lower vasoreactivity noted in hypertension is related or independent of stroke or WMH. TCD, moreover, does not provide simultaneous assessment of vasoreactivity in multiple brain regions. Identifying specific regions that may have lower vasoreactivity in the brain offers an insight to the potential processes by which the brain is affected by hypertension.
Continuous arterial spin labeling (CASL) perfusion MRI can detect cerebral perfusion changes, provide detailed cerebral blood flow mapping in several brain regions, and simultaneously assesses structural brain changes. 10 -12 CASL-MRI, hence, addresses the gaps in our knowledge regarding hypertension and cerebral vasoreactivity. Our group has validated the use of CASL-MRI to assess cerebral vasoreactivity in diabetics and stroke survivors. 8, 13 In this study, we expanded the application of CASL-MRI to assess the relation between hypertension and cerebral vasoreactivity.
Hypertension is also associated with changes in circadian rhythms, most notably lack of nighttime dipping. 14 This, in turn, has been associated with stroke and greater brain atrophy. 15, 16 It is not known whether the potentially impaired cerebrovascular reactivity seen in hypertension is related to elevated blood pressure, lower nighttime dipping, or both.
Our objective was to determine the association between hypertension and cerebral vasoreactivity to CO 2 , after accounting for WMH and previous stroke using CASL-MRI. Our second objective was to investigate the relation between nighttime dipping and vasoreactivity.
Methods

Subjects
Potential subjects were invited to the study using local advertisement in the greater Boston area. All of the evaluations were conducted at the Beth Israel Deaconess Medical Center. Inclusion criteria were age Ն50 years and able to perform study procedures, including ambulatory blood pressure monitoring (ABPM) and brain MRI. Individuals with stroke were allowed in this study as long as they were Ͼ6 months after acute event that affected less than one third of middle cerebral artery territory and had a modified Rankin Scale score Ͻ4. The average time post stroke was 6.1 years. Individuals who were receiving antihypertensive medications were also allowed, but these medications were gradually tapered over 3 days and discontinued before the study for Ն2 days. Anticoagulation and antihyperlipidemic medications were allowed.
Exclusion criteria were diabetes mellitus (history or hemoglobin A1C levels Ͼ7.0 mg/dL), dementia or Alzheimer disease, coronary heart disease or congestive heart failure (identified by history, medications, or clinical examination), hospitalization, chronic renal and liver disease, transplantation, active cancer treatment or previous exposure to chemotherapy or radiation, or symptomatic arrhythmias. The study protocol and the investigators adhered to the principles of the Declaration of Helsinki and Title 45, US Code of Federal Regulations, Part 46, Protection of Human Subjects, Revised November 13, 2001, effective December 13, 2001 . All of the subjects provided written informed consent, and the protocol was approved by the Beth Israel Deaconess Medical Center Institutional Review Board.
We screened potential subjects with detailed medical history and physical and neurological examinations, ECG, and routine laboratory tests. A trained research nurse performed manual blood pressure measurements according to the American Heart Association guidelines. 17 If the participant was receiving antihypertensive medications, then he or she was given instructions to taper off the medication according to a standard protocol. Participants were then admitted for 2 days to the General Clinical Research Center. Two manual blood pressure and heart rate measurements were performed 3 times per day for 2 days. Cognitive assessment was performed using the mini-mental status examination. 18 
Ambulatory Blood Pressure Monitoring
ABPM was recorded from 8:00 AM the first admission day to 8:00 AM the next day using a portable automatic monitor Dynapulse (Pulse Metric, Inc). This monitor has been previously validated against intra-arterial blood pressure measurement with a correlation of 98% (PϽ0.001). 19 Systolic blood pressure (SBP) and diastolic blood pressure (DBP) and heart rate were measured at 20-minute intervals during the day and at 30-minute intervals during the night. They were asked to follow their daily routine resembling the usual daily activities at home documented in a personal diary completed before study initiation. All of the activities performed during the daytime and the sleep and wake times were confirmed using the diary and direct observation.
Dipping and Hypertension Definition
Participants were considered hypertensive if they had history of hypertension or were receiving antihypertensives. Those who were not hypertensive based on their history or medication profile but had elevated blood pressure measurements (Ն135/85 mm Hg on ABPM 20, 21 and average casual blood pressure Ն140/90 mm Hg) were also considered hypertensive (only 2 participants). Dipping was calculated according to the standard formula: (daytime blood pressure Ϫ nighttime blood pressure)/daytime blood pressure ϫ 100. Those who had Ͼ10% nighttime decline in SBP or DBP were considered dippers. 20, 22 
MRI Protocol and Data Analysis
Brain imaging protocol is described elsewhere 8, 23 and was performed 3 hours after completing the ABPM monitoring at the 3T MRI scanner. Briefly, high-resolution anatomic image 3D magnetization prepared rapid gradient echoes were acquired to quantify volume of white matter and gray matter (in cubic centimeters). WMH volume was measured on fluid-attenuated inversion recovery images. In our analyses, we used the WMH volume (in cubic centimeters) divided by intracranial volume to account for head size differences between participants. Cerebral perfusion was measured using CASL. CASL technology uses proton labeling of the water molecules in the blood flowing in the blood vessels to allow for accurate and reproducible measures of perfusion. 11 Labeled and unlabeled images were collected over 2-minute periods during normal breathing, CO 2 rebreathing with 95% air and 5% CO 2 (hypercapnia), and hyperventilation (hypocapnia). Two scans were obtained during each phase, and data were then averaged. End-tidal CO 2 was continuously monitored and averaged over 15-second intervals. Cerebral vasoreactivity was calculated as the slope of the regression between cerebral perfusion and end-tidal CO 2 , in units of milliliters per 100 grams per minute per millimeter of mercury, during normal breathing, CO 2 rebreathing, and hyperventilation. We calculated a global cerebral vasoreactivity slope and regional vasoreactivity slopes in the frontal, parietal, temporal, occipital, and cerebellar regions. In the stroke participants, vasoreactivity measures were calculated for both the stroke and nonstroke hemispheres (please see the online Data Supplement at http://hyper.ahajournals.org for more details).
Statistical Analyses
We used t test or 2 to compare characteristics of the hypertensive and normotensive groups. We used general linear models to investigate the association between hypertension and cerebral vasoreactivity (global and regional). Models were adjusted for age, sex, race/ethnicity, body mass index, antihypertensives, and WMH volume/intracranial cavity. We included WMH because of its effect on vasoreactivity and its close association with hypertension. 9 We calculated the least-square mean vasoreactivity adjusted for covariates when comparing the hypertensive and normotensive groups. Effect size for hypertension was measured using partial eta square ( 2 ). 24 Higher values indicate stronger effect size. We used regression analysis to investigate the association between blood pressure and dipping magnitude (both as a continuous measures) with cerebral vasoreactivity. Models were adjusted for the same covariates. We reported the regression coefficient per 10 mm Hg in the blood pressure analyses and per 10% in the dipping analyses, adjusted for these covariates. Effect size was measured by partial correlations.
Finally, we performed stratified analysis by stroke. We used generalized linear models adjusted for the same covariates, except for stroke. We performed 2 sets of analyses in the stroke group (stroke side and opposite side). To assess if there was regional variation in the impact of hypertension on cerebral vasoreactivity, we used mixed models for correlated data for these analyses, because there was a high correlation between the brain regions within an individual. 25 We calculated difference in the adjusted least-square mean vasoreactivity between hypertensives and normotensives by region. We then tested whether the differences by region were significant.
Results
Sample
Of the 68 participants, 6 did not have complete ABPM data. Therefore, data on 62 individuals were used for this analysis (mean age: 66.7Ϯ1.0 years; 55% women; 84% white). Of those, 40 (65%) were hypertensive (38 were on antihypertensives or were diagnosed with hypertension; and an additional 2 had elevated blood pressure based on ABPM and casual blood pressure measurements). As shown in Table 1 , there were no significant differences between hypertensive and normotensive participants in demographic, clinical, laboratory, and brain gray and white matter volume measures. ABPM indices and lipid measures were different between the 2 groups. Global WMH volume was higher in the hypertensive group, but this did not reach statistical significance.
Hypertension and Vasoreactivity
The mean vasoreactivity in the overall sample was 0.78Ϯ0.05 mL/100 g per minute per millimeter of mercury. As shown in Table 2 , after adjusting for covariates, stroke, and WMH/ intracranial cavity volume, hypertensive participants had significantly lower global vasoreactivity compared with normotensives (Pϭ0.0012). The effect size of hypertension was considerably high (partial 2 ϭ0.32). The association of hypertension with lower vasoreactivity was significant in all of the brain regions except the cerebellum. Figure 1 demonstrates the differences in perfusion at baseline and during hypercapnia and hypocapnia phases between a hypertensive and a normotensive participant.
Blood Pressure, Nighttime Dipping, and Vasoreactivity
Higher SBP, but not DBP, was associated with lower vasoreactivity. For each 10-mm Hg increment in SBP, global vasoreactivity decreased by 0.1 Units (partial R 2 ϭ0.16) after adjusting for demographics, body mass index, stroke, antihypertensives, and WMH/intracranial volume. Regionally, this was only significant in the parietal and occipital lobes. Dipping status was not associated with vasoreactivity (nondippers: 0.77Ϯ0.08 mL/100 g per minute per millimeter of mercury; dippers: 0.77Ϯ0.10 mL/100 g per minute per millimeter of mercury; Pϭ0.76). The magnitudes of dipping in SBP and DBP (as continuous measure) were not related to vasoreactivity. These results are shown in the online Data Supplement (please see Table S1 , available at http://hyper.ahajournals.org).
Estimating the Magnitude of Decreased Vasoreactivity From Hypertension Without Stroke and From Stroke Without Hypertension
Normotensive participants without stroke had the highest global vasoreactivity. On the other hand, hypertensive participants without stroke had similar vasoreactivity as stroke participants (normotension stroke free: 1.38Ϯ0.16 mL/100 g per minute per millimeter of mercury; hypertension stroke free: 0.59Ϯ0.010 mL/100 g per minute per millimeter of mercury; Pϭ0.001 after adjusting for covariates; normotension stroke: 0.47Ϯ0.40 mL/100 g per minute per millimeter of mercury; hypertension stroke: 0.58Ϯ0.35 mL/100 g per minute per millimeter of mercury; Pϭ0.25 in the stroke hemisphere; Pϭ0.57 the nonstroke hemisphere). The regional vasoreactivity results followed the same pattern and are shown in Figure 2 . Hypertensive participants without stroke had comparable vasoreactivity to those with stroke in all of the regions after adjusting for all of the related covariates. When we compared the hypertension-related differences in vasoreactivity in the various brain regions, the decline was greatest in the parietal and frontal regions in nonstroke hypertensive participants as shown in Table 3 .
Discussion
Our findings extend our previous knowledge, which is mostly based on TCD and positron emission tomography scan technology, by demonstrating that hypertension is directly associated with lower cerebral vasoreactivity to CO 2 independent of stroke and WMH. The magnitude of decrease in cerebral vasoreactivity from hypertension in the absence of stroke is comparable to that of stroke. Moreover, there is an inverse association between lower cerebral vasoreactivity and higher SBP but not with nighttime dipping. Regionally, hypertension is associated with lower vasoreactivity in all of the cortical brain regions but is more prominent in the frontal and parietal areas.
To our knowledge, this is the first study using CASL-MRI to assess vasoreactivity in hypertensives. We have reported previously that higher SBP is associated with poor global and regional perfusion using CASL-MRI. 23 Dai et al 26 demonstrated that, in 19 hypertensive participants in the Cardiovascular Health Study, regional blood flow was lower than that in normotensives using CASL-MRI. Hypertension is also associated with lower vasoreactivity, in addition to decreased perfusion. This may further impair the ability to maintain cerebral blood flow during increasing demands and lead to further brain injury. Because lower vasoreactivity maybe associated with cognitive and physical declines, 3,5 this observation may provide a partial explanation for the relation between hypertension and both cognitive impairment and physical disability noted in other studies. 27, 28 The mechanisms of low vasoreactivity in hypertensive individuals are not fully understood. Our study suggests that there are Ն2 potential mechanisms that impair vasoreactivity in hypertension: one indirect mechanism via its relation with stroke and WMH, which eventually lower cerebral vasoreactivity, 29 and another independent of both. Hypertension is associated with significant decrease in NO production in the cerebral circulation, 30 and the ability of the cerebral circulation to respond appropriately to CO 2 is related to endothelial NO production. [31] [32] [33] [34] Non-NO functions of the endothelium are also impaired in hypertension. 35 Adenosine-5Ј-triphosphatedependent Kϩ channel activation may also mediate CO 2 -induced NO activity in the pial arterioles. 36 Hypertension is also associated with structural changes in the blood vessels, such as increased tortuosity and reduced arteriolar branching, which may also affect cerebral vasoreactivity. 37 Of particular concern is that vasoreactivity in stroke-free hypertensives is comparable to that of the stroke participants. This is of great significance, because from the cerebrovascular function perspective, the impact of hypertension is as severe as that of stroke. This suggests that hypertensive individuals without stroke have impaired cerebrovascular function comparable to those who already have stroke. Because impaired cerebrovascular reactivity to CO 2 is related to poor vascular and functional outcomes in various populations, 5, 38 future studies that investigate the impact of antihypertensive medications on cerebral vasoreactivity are important.
Nondipping is associated with worse vascular macrovascular and microvascular brain injury in hypertension. 39, 40 In this study we did not identify an association between dipping and cerebral vasoreactivity. The lack of association in this study may be related to our relatively small sample size. It is also possible that nighttime dipping may not be intimately related to brain perfusion and cerebrovascular reactivity. We have reported previously that nocturnal dipping in blood pressure was not associated with global cerebral perfusion. 23 Regionally, hypertension is related to lower vasoreactivity in all cortical regions. The magnitude of decrease in vasoreactivity from hypertension was greatest in the fornto-parietal regions. These 2 regions are involved in mood and in cognitive and physical performance. 41, 42 We have reported recently that hypertensive individuals have impairments in mobility, cognition, and mood, even in the absence of clinical symptoms or disease. 43 This may shed more light on the possible mechanisms by which hypertension may be related to these impairments.
Although CASL-MRI is still not widely used clinically, this study provides evidence that it can be used to assess vasoreactivity. CASL-MRI requires no contrast. CASL-MRI also addresses previous limitations of TCD, has a relatively low signal:noise ratio, and, hence, is ideal to assess vasoreactivity in the brain.
One limitation of our study is the cross-sectional design, which precludes investigating the temporal relation between hypertension and vasoreactivity. As in most hypertension studies, antihypertensive exposure is an important confounder and limits our ability to study the natural impact of elevated blood pressure. In this study, we addressed this issue by performing our measures off antihypertensives, albeit only for few days for ethical reasons. We also adjusted all of our models for antihypertensive therapy.
Conclusions
Hypertension is associated with low cerebrovascular reactivity to CO 2 independent of existing stroke or WMH. This decrease is similar in magnitude to that of stroke. Although all of the cortical regions are affected, the greatest impact was in the fronto-parietal region. Low vasoreactivity to CO 2 in hypertension may further increase the risk of developing brain-related end-organ damage, beyond its role in microvascular ischemic injury and macrovascular brain disease.
Perspectives
Hypertension is associated with significant impairment in cerebral vasoreactivity. This impairment is comparable to that from stroke. Because impaired cerebral vasoreactivity may be associated with poor functional and cognitive outcomes, prospective studies are needed to investigate the role of hypertension treatment in reversing these effects. Magnetic resonance imaging protocol and data analysis: Brain imaging protocol is described elsewhere and was performed 3 hours after completing the ABPM monitoring at the 3-Tesla MRI scanner.
Sources of Funding
1-2 Briefly, high-resolution anatomical image 3D magnetization prepared rapid gradient echo (MP-RAGE) were acquired to quantify volume of white matter and gray matter (cm 3 ). WMH volume was measured on FLAIR image and was implemented by using the thresholding of hyperintense pixels and a region growing method that allowed an accurate WMH detection, and it is programmed in Interactive Data Language (IDL, ITT Visual Information Solutions, Boulder CO). In our analyses, we used the WMH volume (cm 3 ) divided by intracranial volume to account for head size differences between participants.
Cerebral perfusion was measured using Continuous Arterial Spin Labeling (CASL). CASL technology is non-invasive and uses proton labeling of the water molecules in the blood flowing in the blood vessels to allow for accurate and reproducible measures of perfusion. 3 It is sensitive to perfusion change and can be used for noninvasive mapping of cerebral blood flow (ml·100g -1 ·min -1 ) and vasoreactivity to CO 2 . 3-6 CASL images were acquired using a custom 3D stack of interleaved spirals fast spin echo sequence (T R / T E = 6000/23.8 ms, Echo Train Length = 66, with a 18x18 cm FOV, in the coronal plane and 64 slices with thickness = 3.8 mm, 8 spiral interleaves, 2 averages and a bandwidth = ±62.5 kHz). Labeled and unlabeled images were collected over 2 minute periods during normal breathing, CO 2 rebreathing with 95% air and 5% CO 2 (hypercapnia), and hyperventilation (hypocapnia). Two scans were obtained during each phase and data was then averaged. Quantitative perfusion maps were reconstructed for each condition 6 (Research Systems, Boulder Co). Quantitative perfusion values were derived by segmenting the tissue into gray and white matter on the basis of the T1 maps and by using partition coefficients as described previously. 7 End-tidal CO 2 was continuously monitored and averaged over 15-second intervals. Blood pressure was measured in 1-minute intervals. Cerebral vasoreactivity was calculated as the slope of the regression between cerebral perfusion and end-tidal CO 2 , in units of ml/100gm/min/mmHg, during normal breathing, CO 2 rebreathing, and hyperventilation. Perfusion was measured as the sum of both perfusion in the white and gray matter. We calculated a global cerebral vasoreactivity slope and regional vasoreactivity slopes in the frontal, parietal, temporal, occipital and cerebellar regions. In the stroke participants, vasoreactivity measures were calculated for both the stroke and non-stroke hemispheres. Except for the stratified analysis by stroke, we used the non-stroke hemisphere data in those with history of stroke for our analysis. There was a high correlation between the stroke hemisphere and non-stroke hemisphere vasoreactivity measures (correlation=88%, p<0.001). 
